ALYN Hospital Receives a $2.2M Grant

To Establish the First Research Center in Israel for Pediatric and Adolescent Rehabilitation

ALYN Hospital, Israel’s first and only pediatric and adolescent rehabilitation facility, has been awarded a donation of $2.189 million from The Leona M. and Harry B. Helmsley Charitable Trust, to establish the first center in Israel dedicated to groundbreaking research that will position Israel as a global leader in pediatric and adolescent rehabilitation development.

The Helmsley Charitable Trust is a global philanthropy committed to helping people live better lives today and creating stronger, healthier futures for individuals and communities. Since 2010, Helmsley has contributed over $434 million to Israel, including a donation of $12.5M last year to help fight the coronavirus pandemic.

ALYN Hospital’s new research center will focus on several relevant fields, including  cognitive, orthopedic and neurological rehabilitation, remote rehabilitation, mobility, and more. These are crucial areas to help ALYN’s young patients perform their daily activities and promote their integration into their communities. These patients are in need of rehabilitation due to various circumstances, such as accidents, diseases, birth defects, and developmental issues (such as cerebral palsy).  With the new research center, ALYN Hospital will be able to advance its treatment methods and approach. The research will be conducted in collaboration with other hospitals and organizations in Israel and around the world.

Arie Melamed, General Manager of ALYNnovation, the hospital’s innovation center, has been appointed as the Director of the Research Center, while Prof. Patrice L. (Tamar) Weiss, a world-renowned expert in the field of rehabilitation, will oversee the center’s scientific activities.

Sandor Frankel, a Helmsley Trustee, stated: “Helmsley is pleased to support ALYN Hospital, a distinguished institution qualified to lead the necessary research activities in the field of pediatric and adolescent rehabilitation in Israel, helping millions of young patients in the country and around the world who need innovative and groundbreaking treatments.”

“The new research center will allow us to expand our research and clinical trials, recruit additional professionals in the field, and continue to advance pediatric and adolescent rehabilitation in Israel and around the world,” says ALYN Hospital’s Director General Dr. Maurit Beeri. “The field of child rehabilitation has not received enough attention due to it being relatively limited,” explains Dr. Beeri. “By establishing this research center at the ALYN Hospital, in collaboration with our best researchers, doctors and senior therapists from various health fields, we will take a major step forward in the fields of research and development of technologies for the rehabilitation of children and adolescents.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version